Literature DB >> 28992797

Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.

Y Tal1, R Maoz Segal2, P Langevitz3,4, S Kivity4,5, Z Darnizki1, N Agmon-Levin2,4.   

Abstract

Hydroxychloroquine (HCQ) is widely used to treat autoimmune/rheumatic diseases such as systemic lupus erythematosus (SLE). The immune modulation effects of HCQ have been highlighted as beneficial for maintaining remission of SLE as well as ameliorating skin, joint and other manifestations. Moreover, HCQ exposure for prolonged periods as well as during pregnancy is considered safe, therefore it is recommended for the vast majority of SLE patients. Although HCQ therapy requires follow-up by a specialist, its most common side effects are mild gastrointestinal disturbances, sensitivity to light and skin rashes. Of these side effects, hypersensitivity skin reactions have been suggested to play a role in reduced compliance to HCQ therapy. In the current study we present a two-stage HCQ desensitization protocol that was successfully implemented among 12 out of 13 patients. We exhibit that prolonged HCQ oral desensitization is an effective method for overcoming mild to moderate late hypersensitivity reactions and thoroughly address possible mechanisms of action.

Entities:  

Keywords:  Hydroxychloroquine; Plaquenil; desensitization; pregnancy; systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 28992797     DOI: 10.1177/0961203317735185

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Idiopathic Nonhistaminergic Acquired Angioedema in a Patient with COVID-19.

Authors:  Veronica Azmy; Jemma Benson; Keith Love; Ryan Steele
Journal:  Ann Allergy Asthma Immunol       Date:  2020-07-01       Impact factor: 6.347

2.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.